The FDA has placed a partial hold on three clinical trials investigating nivolumab (Opdivo) based combination treatments in patients with relapsed or refractory multiple myeloma. The announcement follows a couple of months after the discontinuation of two trials of another checkpoint inhibitor pembrolizumab (Keytruda) combined with other treatments in patients with multiple myeloma. The FDA said ...
Check point inhibitor trial grinds to a halt
By Mardi Chapman
11 Sep 2017